THIS INFORMATION
COLLECTION IS APPROVED THROUGH 1/86 SUBJECT TO THE FOLLOWING
CONDITIONS: 1. WITH RESPECT TO "HUMAN" INSULIN, FDA MUST PERMIT AN
HPLC (HIGH peformance liquid chromotography) assay method by
either, (1) adopting THE UPDATED UNITED STATES PHARMACOPEIA (USP)
TESTING PROCEDURES CURRENTLY ANTICIPATED TO BECOME EFFECTIVE ON
1/1/85, OR (2) INITIATING A RULEMAKING ON 1/1/85 TO PERMIT AN HPLC
ASSAY SHOULD THE USP MONOGRAPH NOT INCORPORATE THE HPLC ASSAY BY
THAT DATE. 2. WITH RESPECT TO "ANIMAL" INSULIN, FDA MUST BY 1/1/86
EITHER (1) adopt USP HPLC assay procedures should this method be
incorporated by THE USP BY THAT DATE, OR (2) ISSUE A PROPOSED RULE
TO PERMIT SUCH PROCEDURES IF IT APPEARS UNLIKELY THAT THE USP WILL
NOT AMEND ITS MONOGRAPH TO INCORPORATE AN HPLC ASSAY BY THAT DATE.
APPROVAL IS GRANTED ONLY THROUGH 1/1/86 TO ENSURE THAT CONDITION 2
IS MET, AND TO ASSESS THE DEGREE TO WHICH RELIANCE UPON HPLC FOR
HUMAN INSULIN HAS REDUCED MANUFACTURERS' INVENTORY LAG THAT
RESULTED FROM previous reliance upon rabbit bioassays.
Inventory as of this Action
Requested
Previously Approved
01/31/1986
01/31/1986
08/31/1984
3
0
483
580
0
580
0
0
0
ANALYTICAL DATA PREREQUISITE FOR BATCH
CERTIFICATION WITHOUT WHICH THE BATCH CANNOT LEGALLY BE
DISTRIBUTED. PROGRAM IS MANDATED BY STATUTE A IS SELF-SUPPORTING
THROUGH FEES.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.